Investors are bidding up companies trying to alleviate the coronavirus outbreak, from biotechs working on treatments and vaccines to telemedicine companies catering for the sick stuck at home.
Some are seeking “fast money” trades, diving into smaller biotechs with long shots at a vaccine, while others are hunting for more solid long-term investments that could also be buoyed by the epidemic.
“There has been an incredible amount of interest in the biotech industry in the wake of the coronavirus,” said Thomas Hayes, chairman of Great Hill Capital, the New York-based hedge fund.
您已阅读12%（580字），剩余88%（4228字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。